The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
The company will manufacture a cancer immunotherapy product from 2022
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Subscribe To Our Newsletter & Stay Updated
